Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

导出原文传递

翻译打印收藏纠错

作者： Noel,Clarke ^[1] ; Pawel,Wiechno ^[2] ; Boris,Alekseev ^[3] ; Nuria,Sala ^[4] ; Robert,Jones ^[5] ; Ivo,Kocak ^[6] ; Vincenzo Emanuele,Chiuri ^[7] ; Jacek,Jassem ^[8] ; Aude,Fléchon ^[9] ; Charles,Redfern ^[10] ; Carsten,Goessl ^[11] ; Joseph,Burgents ^[11] ; Robert,Kozarski ^[12] ; Darren,Hodgson ^[13] ; Maria,Learoyd ^[12] ; Fred,Saad ^[14]

作者单位： The Christie and Salford Royal Hospitals, Manchester, UK. Electronic address: noel.clarke@christie.nhs.uk. ^[1] Maria Skłodowska-Curie Memorial Cancer Centre, Warsaw, Poland. ^[2] Hertzen Moscow Cancer Research Institute, Moscow, Russia. ^[3] Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain. ^[4] Velindre Cancer Centre, Cardiff University, Cardiff, UK. ^[5] Masaryk Memorial Cancer Institute, Brno, Czech Republic. ^[6] Ospedale Vito Fazzi, Lecce, Italy. ^[7] Medical University of Gdańsk, Gdańsk, Poland. ^[8] Centre Léon Bérard, Lyon, France. ^[9] Sharp HealthCare, San Diego, CA, USA. ^[10] AstraZeneca, Gaithersburg, MD, USA. ^[11] AstraZeneca, Cambridge, UK. ^[12] AstraZeneca, Macclesfield, UK. ^[13] Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. ^[14]